2024
Development and evaluation of a questionnaire to capture environmental and occupational inhalational exposures in adults with fibrotic interstitial lung disease
Swaminathan A, McFatrich M, Mkumba L, Wright L, Redlich C, Snyder L, Reeve B, Patel D, Gulati M. Development and evaluation of a questionnaire to capture environmental and occupational inhalational exposures in adults with fibrotic interstitial lung disease. Respiratory Research 2024, 25: 372. PMID: 39407223, PMCID: PMC11481565, DOI: 10.1186/s12931-024-03000-z.Peer-Reviewed Original ResearchConceptsCognitive interviewsContent validityExposure questionnaireMultidisciplinary teamSemi-structured interview guideEvidence of content validityFibrosing ILDsInterstitial lung diseaseRelevant exposuresFibrotic interstitial lung diseaseClinically relevant exposuresTrained interviewersInterview guideAssessment QuestionnaireQuestionnaireInterviewsLung diseaseAdultsTeamClinicPatientsSource of misunderstandingOccupational inhalation exposureValidityDisease
2022
Cough-Specific Quality of Life Predicts Disease Progression Among Patients With Interstitial Lung Disease Data From the Pulmonary Fibrosis Foundation Patient Registry
Lee J, White E, Freiheit E, Scholand M, Strek M, Podolanczuk A, Patel N, Foundation P, Bascom R, Belloli E, Bhatt N, Bhorade S, Case A, Castriotta R, Criner G, Danoff S, De Andrade J, Desai A, Glassberg M, Glazer C, Gulati M, Gupta N, Hamblin M, Huie T, Kaner R, Kass D, Kim H, Kreider M, Lancaster L, Lasky J, Limper A, Montesi S, Mooney J, Morrison L, Nambiar A, Nathan S, Natt B, Paul T, Perez R, Podolanczuk A, Raghu G, Scholand M, Shifren A, Strek M, Todd N, Walia R, Weight S, Whelan T, Wolters P. Cough-Specific Quality of Life Predicts Disease Progression Among Patients With Interstitial Lung Disease Data From the Pulmonary Fibrosis Foundation Patient Registry. CHEST Journal 2022, 162: 603-613. PMID: 35337809, PMCID: PMC9808640, DOI: 10.1016/j.chest.2022.03.025.Peer-Reviewed Original ResearchMeSH KeywordsCoughDisease ProgressionHumansIdiopathic Pulmonary FibrosisLung Diseases, InterstitialQuality of LifeRegistriesConceptsInterstitial lung diseaseCough-specific QoLLeicester Cough QuestionnaireLung transplantationRespiratory hospitalizationsHigh riskPatient factorsLung diseaseDisease progressionLCQ scoreDisease severityMultivariable Cox regression modelsMultivariable proportional hazards modelsPatient-centered clinical outcomesBaseline disease severityGastroesophageal reflux diseaseHealth-related qualityRespiratory-related hospitalizationsCough-specific qualityIdiopathic pulmonary fibrosisPulmonary function parametersCox regression modelProportional hazards modelMultivariable proportional odds modelProportional odds model
2020
The Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and Methods.
Wang BR, Edwards R, Freiheit EA, Ma Y, Burg C, de Andrade J, Lancaster L, Lindell K, Nathan SD, Raghu G, Gibson K, Gulati M, Mason W, Noth I, Schmidt B, Spino C, Staszak S, Stauffer J, Wolters PJ, Cosgrove GP, Flaherty KR. The Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and Methods. Annals Of The American Thoracic Society 2020, 17: 1620-1628. PMID: 32776789, DOI: 10.1513/annalsats.202001-035sd.Peer-Reviewed Original ResearchMeSH KeywordsAgedHumansIdiopathic Pulmonary FibrosisLung Diseases, InterstitialMaleProspective StudiesRegistriesRetrospective StudiesConceptsInterstitial lung diseasePatient RegistryClinician accessLarge multicenter registryMean diffusing capacityPositive smoking historyPercent of patientsIdiopathic pulmonary fibrosisTime of enrollmentIndividuals 18 yearsMulticenter registrySmoking historyPulmonary fibrosisSupplemental oxygenVital capacityLung diseaseMean agePatient populationAntifibrotic therapyApplicable biomarkersClinical informationDiffusing capacityPatientsClinical sitesRegistryEssential Components of an Interstitial Lung Disease Clinic Results From a Delphi Survey and Patient Focus Group Analysis
Graney B, He C, Marll M, Matson S, Bianchi P, Cosgrove G, Lee J, Collaborators P, Abrencillo R, Bascom R, Scholand M, Bhatt N, Case A, Chaudhary S, Culver D, Danoff S, Desai A, Dilling D, Glazer C, Gulati M, Gupta N, Hamblin M, Hamzeh N, Huie T, Kim H, King C, Kreider M, Lacamera P, Lancaster L, Luckhardt T, Mageto Y, Kottman R, McCormick J, Mehrad B, Menon P, Montesi S, Mooney J, Moore D, Moua T, Nambiar A, Oldham J, Patel D, Paul T, Perez R, Podolanczuk A, Ramaswamy M, Roe D, Saad M, Sandbo N, Schaumberg T, Schmidt S, Shea B, Shifren A, Strek M, Thavarajah K, Todd N, Veeraraghavan S, Weight S, Wolters P, Zibrak J. Essential Components of an Interstitial Lung Disease Clinic Results From a Delphi Survey and Patient Focus Group Analysis. CHEST Journal 2020, 159: 1517-1530. PMID: 33031832, PMCID: PMC7534733, DOI: 10.1016/j.chest.2020.09.256.Peer-Reviewed Original ResearchMeSH KeywordsAmbulatory Care FacilitiesColoradoDelphi TechniqueFocus GroupsHumansLung Diseases, InterstitialModels, OrganizationalUnited StatesConceptsInterstitial lung diseaseILD clinicCaregiver focus groupsPhysician expertsInterstitial lung disease clinicPatient-centered medical careManagement of patientsPulmonary Fibrosis FoundationDelphi surveyILD expertsILD patientsDisease clinicMultidisciplinary careLung diseasePatient outcomesFocus groupsClinicPatientsMedical careStudy designRound 1Essential componentThree-roundCareFocus group analysis
2016
Netrin‐1 Regulates Fibrocyte Accumulation in the Decellularized Fibrotic Sclerodermatous Lung Microenvironment and in Bleomycin‐Induced Pulmonary Fibrosis
Sun H, Zhu Y, Pan H, Chen X, Balestrini JL, Lam TT, Kanyo JE, Eichmann A, Gulati M, Fares WH, Bai H, Feghali-Bostwick CA, Gan Y, Peng X, Moore MW, White ES, Sava P, Gonzalez AL, Cheng Y, Niklason LE, Herzog EL. Netrin‐1 Regulates Fibrocyte Accumulation in the Decellularized Fibrotic Sclerodermatous Lung Microenvironment and in Bleomycin‐Induced Pulmonary Fibrosis. Arthritis & Rheumatology 2016, 68: 1251-1261. PMID: 26749424, PMCID: PMC5547894, DOI: 10.1002/art.39575.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibiotics, AntineoplasticAntibodies, NeutralizingBiomechanical PhenomenaBleomycinCase-Control StudiesCell DifferentiationCollagenCollagen Type ICollagen Type I, alpha 1 ChainFibrosisFlow CytometryFluorescent Antibody TechniqueHeterozygoteHumansLeukocyte Common AntigensLeukocytes, MononuclearLungLung Diseases, InterstitialMiceMice, KnockoutMicroscopy, Electron, ScanningNerve Growth FactorsNetrin-1ProteomicsPulmonary FibrosisReverse Transcriptase Polymerase Chain ReactionScleroderma, SystemicTissue ScaffoldsTumor Suppressor ProteinsConceptsSSc-related interstitial lung diseaseInterstitial lung diseaseFibrocyte accumulationNetrin-1Lung extracellular matrixPulmonary fibrosisLung scaffoldsBleomycin-Induced Pulmonary FibrosisPeripheral blood mononuclear cellsBlood mononuclear cellsHealthy control subjectsNovel therapeutic targetSystemic sclerosisExtracellular matrixLung fibrosisLung diseaseMononuclear cellsControl subjectsLung microenvironmentHealthy controlsScleroderma patientsAberrant anatomyLung matrixPatientsTherapeutic target
2015
Asbestosis and environmental causes of usual interstitial pneumonia
Gulati M, Redlich CA. Asbestosis and environmental causes of usual interstitial pneumonia. Current Opinion In Pulmonary Medicine 2015, 21: 193-200. PMID: 25621562, PMCID: PMC4472384, DOI: 10.1097/mcp.0000000000000144.Peer-Reviewed Original ResearchMeSH KeywordsAsbestosAsbestosisEnvironmental ExposureHumansLung Diseases, InterstitialOccupational DiseasesRisk FactorsConceptsIdiopathic pulmonary fibrosisUsual interstitial pneumoniaInterstitial pneumoniaDevelopment of IPFUsual interstitial pneumonia patternRecent epidemiologic investigationsEnvironmental exposuresFibrotic lung diseaseInterstitial pneumonia patternExposure-disease relationshipsIPF patientsPneumonia patternClinical courseIPF diagnosisPulmonary fibrosisHistopathologic patternLung diseaseAsbestos exposureRadiographic changesOverall burdenAsbestosis patientsClinical challengeEpidemiologic studiesCase controlAgricultural exposures
2014
Supportive Care for Patients with Pulmonary Complications of Connective Tissue Disease
Gulati M, Antin-Ozerkis D. Supportive Care for Patients with Pulmonary Complications of Connective Tissue Disease. Seminars In Respiratory And Critical Care Medicine 2014, 35: 274-282. PMID: 24668542, DOI: 10.1055/s-0034-1371538.Peer-Reviewed Original ResearchMeSH KeywordsConnective Tissue DiseasesHolistic HealthHospice CareHumansHypertension, PulmonaryLung Diseases, InterstitialQuality of LifeRespiration, ArtificialTerminal CareConceptsConnective tissue diseaseQuality of lifePulmonary complicationsSupportive careTissue diseaseLung diseaseAdvanced lung diseaseGastroesophageal reflux diseaseGlucocorticoid-induced osteoporosisInterstitial lung diseaseManagement of patientsLung transplantationTreatable comorbiditiesPulmonary hypertensionPulmonary rehabilitationReflux diseaseSignificant comorbiditiesMechanical ventilationPatient's symptomsSupplemental oxygenPulmonary disordersSleep disturbancesCardiovascular diseaseMood disordersSupportive measures
2012
Newly Recognized Occupational and Environmental Causes of Chronic Terminal Airways and Parenchymal Lung Disease
Sauler M, Gulati M. Newly Recognized Occupational and Environmental Causes of Chronic Terminal Airways and Parenchymal Lung Disease. Clinics In Chest Medicine 2012, 33: 667-680. PMID: 23153608, PMCID: PMC3515663, DOI: 10.1016/j.ccm.2012.09.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsParenchymal lung diseaseExposure-disease relationshipsLung diseaseTerminal airwaysDiffuse parenchymal lung diseaseWorld Trade Center disasterChronic formHigh indexNovel exposureDiseaseEnvironmental exposuresHealth investigatorsWorker surveillanceAirwayExposureEnvironmental causesPotential toxicityCliniciansSuspicionNylon flockBiomarkersChitinase 1 Is a Biomarker for and Therapeutic Target in Scleroderma-Associated Interstitial Lung Disease That Augments TGF-β1 Signaling
Lee CG, Herzog EL, Ahangari F, Zhou Y, Gulati M, Lee CM, Peng X, Feghali-Bostwick C, Jimenez SA, Varga J, Elias JA. Chitinase 1 Is a Biomarker for and Therapeutic Target in Scleroderma-Associated Interstitial Lung Disease That Augments TGF-β1 Signaling. The Journal Of Immunology 2012, 189: 2635-2644. PMID: 22826322, PMCID: PMC4336775, DOI: 10.4049/jimmunol.1201115.Peer-Reviewed Original ResearchConceptsInterstitial lung diseaseTGF-β1 signalingPulmonary fibrosisLung diseaseTherapeutic targetScleroderma-Associated Interstitial Lung DiseaseDifferent patient cohortsTGF-β receptor 1Wild-type miceTGF-β1 effectsSSc-ILDLung involvementSSc patientsSystemic sclerosisPulmonary responseLung fibrosisPoor prognosisCHIT1 activityPatient cohortPathogenetic mechanismsReceptor expressionMurine modelingTGF-β1Disease severityPotential biomarkers
2011
Role of semaphorin 7a signaling in transforming growth factor β1–induced lung fibrosis and scleroderma‐related interstitial lung disease
Gan Y, Reilkoff R, Peng X, Russell T, Chen Q, Mathai SK, Homer R, Gulati M, Siner J, Elias J, Bucala R, Herzog E. Role of semaphorin 7a signaling in transforming growth factor β1–induced lung fibrosis and scleroderma‐related interstitial lung disease. Arthritis & Rheumatism 2011, 63: 2484-2494. PMID: 21484765, PMCID: PMC3651701, DOI: 10.1002/art.30386.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsInterstitial lung diseaseBone marrow-derived cellsMarrow-derived cellsSemaphorin 7AGrowth factor-β1Lung diseaseLung fibrosisFactor-β1Human peripheral blood mononuclear cellsNormal human peripheral blood mononuclear cellsSemaphorin 7a expressionBone marrow transplantationBlood mononuclear cellsReceptor β1 integrinΒ1 integrinFibrocyte differentiationMarrow transplantationPulmonary fibrosisMononuclear cellsProfibrotic effectsTGFβ1 geneMurine modelFibrosisTissue accumulationDiagnostic assessment of patients with interstitial lung disease
Gulati M. Diagnostic assessment of patients with interstitial lung disease. Npj Primary Care Respiratory Medicine 2011, 20: 120-127. PMID: 21509417, PMCID: PMC6549811, DOI: 10.4104/pcrj.2010.00079.Peer-Reviewed Original ResearchMeSH KeywordsBiopsyDiagnosis, DifferentialHumansLung Diseases, InterstitialReproducibility of ResultsRespiratory Function TestsTomography, X-Ray ComputedConceptsInterstitial lung diseaseChronic obstructive pulmonary diseaseLung diseaseSurgical lung biopsyObstructive pulmonary diseaseConnective tissue diseasePrimary care settingHistory of symptomsTomography chest scanILD formsLung biopsyRespiratory symptomsPulmonary diseaseClinical cluesPulmonary diagnosisTissue diseaseILD casesPhysical examinationDrug exposureGeneral practitionersDiagnostic evaluationCare settingsStructured historyChest scansDisease
2010
Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype
Mathai SK, Gulati M, Peng X, Russell TR, Shaw AC, Rubinowitz AN, Murray LA, Siner JM, Antin-Ozerkis DE, Montgomery RR, Reilkoff RA, Bucala RJ, Herzog EL. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Laboratory Investigation 2010, 90: 812-823. PMID: 20404807, PMCID: PMC3682419, DOI: 10.1038/labinvest.2010.73.Peer-Reviewed Original ResearchConceptsInterstitial lung diseaseSSc-ILD patientsSSc-ILDIL-10Normal controlsProfibrotic cellsSystemic sclerosisLung diseaseCollagen-producing cellsMCP-1Profibrotic phenotypeSSc-related interstitial lung diseaseFlow cytometryPeripheral blood profilesSSc-ILD cohortsIL-10 secretionSystemic sclerosis patientsExpression of CD163Blood of patientsHealthy aged controlsCultured CD14Profibrotic characteristicsProfibrotic mediatorsTNF levelsSclerosis patients